{"idB": "1006281_12_item7_p23_s0", "idA": "1006281_11_item7_p10_s1", "sentA": "The merger transaction was treated as a recapitalization for accounting purposes and, as such, the results of operations discussed below are those of Protalix Ltd.", "sentB": "According to Genzyme, it has suffered interruptions and other limitations in its Cerezyme production and release since September 2009 and, as a result, Cerezyme supplies have been limited.", "type": 1, "words": ["<tag1>", "The", "merger", "transaction", "was", "treated", "as", "a", "recapitalization", "for", "accounting", "purposes", "and,", "as", "such,", "the", "results", "of", "operations", "discussed", "below", "are", "those", "of", "Protalix", "Ltd.", "<tag2>", "According", "to", "Genzyme,", "it", "has", "suffered", "interruptions", "and", "other", "limitations", "in", "its", "Cerezyme", "production", "and", "release", "since", "September", "2009", "and,", "as", "a", "result,", "Cerezyme", "supplies", "have", "been", "limited.", "<tag3>"], "wordsA": ["The", "merger", "transaction", "was", "treated", "as", "a", "recapitalization", "for", "accounting", "purposes", "and,", "as", "such,", "the", "results", "of", "operations", "discussed", "below", "are", "those", "of", "Protalix", "Ltd."], "wordsB": ["According", "to", "Genzyme,", "it", "has", "suffered", "interruptions", "and", "other", "limitations", "in", "its", "Cerezyme", "production", "and", "release", "since", "September", "2009", "and,", "as", "a", "result,", "Cerezyme", "supplies", "have", "been", "limited."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p2_s5", "idA": "1006281_11_item7_p14_s4", "sentA": "Actual results may differ from these estimates under different assumptions or conditions.", "sentB": "At the time the NDA was submitted, full data from these trials was not available.", "type": 1, "words": ["<tag1>", "Actual", "results", "may", "differ", "from", "these", "estimates", "under", "different", "assumptions", "or", "conditions.", "<tag2>", "At", "the", "time", "the", "NDA", "was", "submitted,", "full", "data", "from", "these", "trials", "was", "not", "available.", "<tag3>"], "wordsA": ["Actual", "results", "may", "differ", "from", "these", "estimates", "under", "different", "assumptions", "or", "conditions."], "wordsB": ["At", "the", "time", "the", "NDA", "was", "submitted,", "full", "data", "from", "these", "trials", "was", "not", "available."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p30_s1", "idA": "1006281_11_item7_p15_s0", "sentA": "The currency of the primary economic environment in which our operations are conducted is the dollar.", "sentB": "Our pr-antiTNF product candidate has an amino acid sequence that is similar to Enbrel which is one of the treatments for patients of those diseases.", "type": 1, "words": ["<tag1>", "The", "currency", "of", "the", "primary", "economic", "environment", "in", "which", "our", "operations", "are", "conducted", "is", "the", "dollar.", "<tag2>", "Our", "pr-antiTNF", "product", "candidate", "has", "an", "amino", "acid", "sequence", "that", "is", "similar", "to", "Enbrel", "which", "is", "one", "of", "the", "treatments", "for", "patients", "of", "those", "diseases.", "<tag3>"], "wordsA": ["The", "currency", "of", "the", "primary", "economic", "environment", "in", "which", "our", "operations", "are", "conducted", "is", "the", "dollar."], "wordsB": ["Our", "pr-antiTNF", "product", "candidate", "has", "an", "amino", "acid", "sequence", "that", "is", "similar", "to", "Enbrel", "which", "is", "one", "of", "the", "treatments", "for", "patients", "of", "those", "diseases."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p3_s8", "idA": "1006281_11_item7_p15_s0", "sentA": "The currency of the primary economic environment in which our operations are conducted is the dollar.", "sentB": "A three-month extension cycle is the standard period granted.", "type": 1, "words": ["<tag1>", "The", "currency", "of", "the", "primary", "economic", "environment", "in", "which", "our", "operations", "are", "conducted", "is", "the", "dollar.", "<tag2>", "A", "three-month", "extension", "cycle", "is", "the", "standard", "period", "granted.", "<tag3>"], "wordsA": ["The", "currency", "of", "the", "primary", "economic", "environment", "in", "which", "our", "operations", "are", "conducted", "is", "the", "dollar."], "wordsB": ["A", "three-month", "extension", "cycle", "is", "the", "standard", "period", "granted."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p5_s0", "idA": "1006281_11_item7_p15_s1", "sentA": "As we have no significant source of revenues, we considered the currency of the primary economic environment to be the currency in which we expend cash.", "sentB": "As part of its ongoing review of the MAA, the EMA delivered a list of outstanding points to be addressed by the applicant.", "type": 1, "words": ["<tag1>", "As", "we", "have", "no", "significant", "source", "of", "revenues,", "we", "considered", "the", "currency", "of", "the", "primary", "economic", "environment", "to", "be", "the", "currency", "in", "which", "we", "expend", "cash.", "<tag2>", "As", "part", "of", "its", "ongoing", "review", "of", "the", "MAA,", "the", "EMA", "delivered", "a", "list", "of", "outstanding", "points", "to", "be", "addressed", "by", "the", "applicant.", "<tag3>"], "wordsA": ["As", "we", "have", "no", "significant", "source", "of", "revenues,", "we", "considered", "the", "currency", "of", "the", "primary", "economic", "environment", "to", "be", "the", "currency", "in", "which", "we", "expend", "cash."], "wordsB": ["As", "part", "of", "its", "ongoing", "review", "of", "the", "MAA,", "the", "EMA", "delivered", "a", "list", "of", "outstanding", "points", "to", "be", "addressed", "by", "the", "applicant."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p5_s3", "idA": "1006281_11_item7_p17_s2", "sentA": "If we determine that there are multiple units of accounting, the consideration from the arrangement is allocated among the separate units based on a relative fair value allocation.", "sentB": "The EU orphan drug regulation provides for the possibility of such a challenge, and for an exception to this exclusivity to be granted, based on a number of factors, including contribution to patient care, clinical, supply, capacity and others.", "type": 1, "words": ["<tag1>", "If", "we", "determine", "that", "there", "are", "multiple", "units", "of", "accounting,", "the", "consideration", "from", "the", "arrangement", "is", "allocated", "among", "the", "separate", "units", "based", "on", "a", "relative", "fair", "value", "allocation.", "<tag2>", "The", "EU", "orphan", "drug", "regulation", "provides", "for", "the", "possibility", "of", "such", "a", "challenge,", "and", "for", "an", "exception", "to", "this", "exclusivity", "to", "be", "granted,", "based", "on", "a", "number", "of", "factors,", "including", "contribution", "to", "patient", "care,", "clinical,", "supply,", "capacity", "and", "others.", "<tag3>"], "wordsA": ["If", "we", "determine", "that", "there", "are", "multiple", "units", "of", "accounting,", "the", "consideration", "from", "the", "arrangement", "is", "allocated", "among", "the", "separate", "units", "based", "on", "a", "relative", "fair", "value", "allocation."], "wordsB": ["The", "EU", "orphan", "drug", "regulation", "provides", "for", "the", "possibility", "of", "such", "a", "challenge,", "and", "for", "an", "exception", "to", "this", "exclusivity", "to", "be", "granted,", "based", "on", "a", "number", "of", "factors,", "including", "contribution", "to", "patient", "care,", "clinical,", "supply,", "capacity", "and", "others."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p12_s2", "idA": "1006281_11_item7_p25_s1", "sentA": "Each grant is deducted from the related research and development expenses as the costs are incurred.", "sentB": "Furthermore, those patients who were followed specifically for their bone parameters using Quantitative Chemical Shift Imaging (QCSI) MRI continued to show bone marrow improvement over time.", "type": 1, "words": ["<tag1>", "Each", "grant", "is", "deducted", "from", "the", "related", "research", "and", "development", "expenses", "as", "the", "costs", "are", "incurred.", "<tag2>", "Furthermore,", "those", "patients", "who", "were", "followed", "specifically", "for", "their", "bone", "parameters", "using", "Quantitative", "Chemical", "Shift", "Imaging", "(QCSI)", "MRI", "continued", "to", "show", "bone", "marrow", "improvement", "over", "time.", "<tag3>"], "wordsA": ["Each", "grant", "is", "deducted", "from", "the", "related", "research", "and", "development", "expenses", "as", "the", "costs", "are", "incurred."], "wordsB": ["Furthermore,", "those", "patients", "who", "were", "followed", "specifically", "for", "their", "bone", "parameters", "using", "Quantitative", "Chemical", "Shift", "Imaging", "(QCSI)", "MRI", "continued", "to", "show", "bone", "marrow", "improvement", "over", "time."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p3_s5", "idA": "1006281_11_item7_p30_s2", "sentA": "We filed an NDA for taliglucerase alfa with the FDA in the last quarter of 2009 and received a PDUFA date of February 25, 2011.", "sentB": "In its notification, the FDA stated that its decision related to certain clinical information regarding taliglucerase alfa we had submitted in November 2011 in response to an FDA request.", "type": 1, "words": ["<tag1>", "We", "filed", "an", "NDA", "for", "taliglucerase", "alfa", "with", "the", "FDA", "in", "the", "last", "quarter", "of", "2009", "and", "received", "a", "PDUFA", "date", "of", "February", "25,", "2011.", "<tag2>", "In", "its", "notification,", "the", "FDA", "stated", "that", "its", "decision", "related", "to", "certain", "clinical", "information", "regarding", "taliglucerase", "alfa", "we", "had", "submitted", "in", "November", "2011", "in", "response", "to", "an", "FDA", "request.", "<tag3>"], "wordsA": ["We", "filed", "an", "NDA", "for", "taliglucerase", "alfa", "with", "the", "FDA", "in", "the", "last", "quarter", "of", "2009", "and", "received", "a", "PDUFA", "date", "of", "February", "25,", "2011."], "wordsB": ["In", "its", "notification,", "the", "FDA", "stated", "that", "its", "decision", "related", "to", "certain", "clinical", "information", "regarding", "taliglucerase", "alfa", "we", "had", "submitted", "in", "November", "2011", "in", "response", "to", "an", "FDA", "request."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p13_s1", "idA": "1006281_11_item7_p30_s3", "sentA": "In addition, we submitted a marketing application to the Israeli MOH and an MAA to each of the EMEA and ANVISA in the fourth quarter of 2010 regarding taliglucerase alfa.", "sentB": "The results of the switchover trial demonstrate that over the nine-month treatment period, patients remained stable with regard to spleen volume, liver volume, platelet count and hemoglobin concentration, the efficacy endpoints of the switchover trial, after switching from Cerezyme to taliglucerase alfa.", "type": 1, "words": ["<tag1>", "In", "addition,", "we", "submitted", "a", "marketing", "application", "to", "the", "Israeli", "MOH", "and", "an", "MAA", "to", "each", "of", "the", "EMEA", "and", "ANVISA", "in", "the", "fourth", "quarter", "of", "2010", "regarding", "taliglucerase", "alfa.", "<tag2>", "The", "results", "of", "the", "switchover", "trial", "demonstrate", "that", "over", "the", "nine-month", "treatment", "period,", "patients", "remained", "stable", "with", "regard", "to", "spleen", "volume,", "liver", "volume,", "platelet", "count", "and", "hemoglobin", "concentration,", "the", "efficacy", "endpoints", "of", "the", "switchover", "trial,", "after", "switching", "from", "Cerezyme", "to", "taliglucerase", "alfa.", "<tag3>"], "wordsA": ["In", "addition,", "we", "submitted", "a", "marketing", "application", "to", "the", "Israeli", "MOH", "and", "an", "MAA", "to", "each", "of", "the", "EMEA", "and", "ANVISA", "in", "the", "fourth", "quarter", "of", "2010", "regarding", "taliglucerase", "alfa."], "wordsB": ["The", "results", "of", "the", "switchover", "trial", "demonstrate", "that", "over", "the", "nine-month", "treatment", "period,", "patients", "remained", "stable", "with", "regard", "to", "spleen", "volume,", "liver", "volume,", "platelet", "count", "and", "hemoglobin", "concentration,", "the", "efficacy", "endpoints", "of", "the", "switchover", "trial,", "after", "switching", "from", "Cerezyme", "to", "taliglucerase", "alfa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p9_s0", "idA": "1006281_11_item7_p30_s3", "sentA": "In addition, we submitted a marketing application to the Israeli MOH and an MAA to each of the EMEA and ANVISA in the fourth quarter of 2010 regarding taliglucerase alfa.", "sentB": "In February 2010, the Israeli MOH completed a successful GMP audit of our manufacturing facilities in Carmiel, Israel.", "type": 1, "words": ["<tag1>", "In", "addition,", "we", "submitted", "a", "marketing", "application", "to", "the", "Israeli", "MOH", "and", "an", "MAA", "to", "each", "of", "the", "EMEA", "and", "ANVISA", "in", "the", "fourth", "quarter", "of", "2010", "regarding", "taliglucerase", "alfa.", "<tag2>", "In", "February", "2010,", "the", "Israeli", "MOH", "completed", "a", "successful", "GMP", "audit", "of", "our", "manufacturing", "facilities", "in", "Carmiel,", "Israel.", "<tag3>"], "wordsA": ["In", "addition,", "we", "submitted", "a", "marketing", "application", "to", "the", "Israeli", "MOH", "and", "an", "MAA", "to", "each", "of", "the", "EMEA", "and", "ANVISA", "in", "the", "fourth", "quarter", "of", "2010", "regarding", "taliglucerase", "alfa."], "wordsB": ["In", "February", "2010,", "the", "Israeli", "MOH", "completed", "a", "successful", "GMP", "audit", "of", "our", "manufacturing", "facilities", "in", "Carmiel,", "Israel."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p3_s7", "idA": "1006281_11_item7_p37_s0", "sentA": "The guidance allows companies to estimate the expected term of the option rather than simply using the contractual term of an option.", "sentB": "As this information was requested and provided within 90 days of the February 1, 2012 PDUFA goal date, the FDA had the option to extend the PDUFA goal date to provide adequate time for the FDA to complete its review.", "type": 1, "words": ["<tag1>", "The", "guidance", "allows", "companies", "to", "estimate", "the", "expected", "term", "of", "the", "option", "rather", "than", "simply", "using", "the", "contractual", "term", "of", "an", "option.", "<tag2>", "As", "this", "information", "was", "requested", "and", "provided", "within", "90", "days", "of", "the", "February", "1,", "2012", "PDUFA", "goal", "date,", "the", "FDA", "had", "the", "option", "to", "extend", "the", "PDUFA", "goal", "date", "to", "provide", "adequate", "time", "for", "the", "FDA", "to", "complete", "its", "review.", "<tag3>"], "wordsA": ["The", "guidance", "allows", "companies", "to", "estimate", "the", "expected", "term", "of", "the", "option", "rather", "than", "simply", "using", "the", "contractual", "term", "of", "an", "option."], "wordsB": ["As", "this", "information", "was", "requested", "and", "provided", "within", "90", "days", "of", "the", "February", "1,", "2012", "PDUFA", "goal", "date,", "the", "FDA", "had", "the", "option", "to", "extend", "the", "PDUFA", "goal", "date", "to", "provide", "adequate", "time", "for", "the", "FDA", "to", "complete", "its", "review."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p30_s0", "idA": "1006281_11_item7_p3_s2", "sentA": "In December 2009, we filed a proposed pediatric investigation plan to the Pediatric Committee of the EMEA which was approved during the first quarter of 2010, and have since initiated pediatric studies.", "sentB": "In September 2009, we announced preliminary preclinical data regarding pr-antiTNF.", "type": 1, "words": ["<tag1>", "In", "December", "2009,", "we", "filed", "a", "proposed", "pediatric", "investigation", "plan", "to", "the", "Pediatric", "Committee", "of", "the", "EMEA", "which", "was", "approved", "during", "the", "first", "quarter", "of", "2010,", "and", "have", "since", "initiated", "pediatric", "studies.", "<tag2>", "In", "September", "2009,", "we", "announced", "preliminary", "preclinical", "data", "regarding", "pr-antiTNF.", "<tag3>"], "wordsA": ["In", "December", "2009,", "we", "filed", "a", "proposed", "pediatric", "investigation", "plan", "to", "the", "Pediatric", "Committee", "of", "the", "EMEA", "which", "was", "approved", "during", "the", "first", "quarter", "of", "2010,", "and", "have", "since", "initiated", "pediatric", "studies."], "wordsB": ["In", "September", "2009,", "we", "announced", "preliminary", "preclinical", "data", "regarding", "pr-antiTNF."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p10_s1", "idA": "1006281_11_item7_p40_s4", "sentA": "For the term of each grant of our options, the historical volatility was calculated based upon the overall trading history of the common stock of comparable companies.", "sentB": "In June 2011, ANVISA completed a successful GMP audit of the facility and determined that the facility is acceptable and in December 2011, the IMB completed a successful GMP audit of our facility and issued a Certificate of GMP Compliance of a Manufacturer for the facility.", "type": 1, "words": ["<tag1>", "For", "the", "term", "of", "each", "grant", "of", "our", "options,", "the", "historical", "volatility", "was", "calculated", "based", "upon", "the", "overall", "trading", "history", "of", "the", "common", "stock", "of", "comparable", "companies.", "<tag2>", "In", "June", "2011,", "ANVISA", "completed", "a", "successful", "GMP", "audit", "of", "the", "facility", "and", "determined", "that", "the", "facility", "is", "acceptable", "and", "in", "December", "2011,", "the", "IMB", "completed", "a", "successful", "GMP", "audit", "of", "our", "facility", "and", "issued", "a", "Certificate", "of", "GMP", "Compliance", "of", "a", "Manufacturer", "for", "the", "facility.", "<tag3>"], "wordsA": ["For", "the", "term", "of", "each", "grant", "of", "our", "options,", "the", "historical", "volatility", "was", "calculated", "based", "upon", "the", "overall", "trading", "history", "of", "the", "common", "stock", "of", "comparable", "companies."], "wordsB": ["In", "June", "2011,", "ANVISA", "completed", "a", "successful", "GMP", "audit", "of", "the", "facility", "and", "determined", "that", "the", "facility", "is", "acceptable", "and", "in", "December", "2011,", "the", "IMB", "completed", "a", "successful", "GMP", "audit", "of", "our", "facility", "and", "issued", "a", "Certificate", "of", "GMP", "Compliance", "of", "a", "Manufacturer", "for", "the", "facility."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p2_s4", "idA": "1006281_11_item7_p45_s1", "sentA": "This income resulted primarily from our share of the approximately $21.8 million of revenues generated by Pfizer s sale of taliglucerase alfa to the Ministry of Health of Brazil under the short term supply agreement during Pfizer s 2010 fiscal year.", "sentB": "In the clinical section of the CRL, the FDA requested additional data from our ongoing switchover trial and our long-term extension trial.", "type": 1, "words": ["<tag1>", "This", "income", "resulted", "primarily", "from", "our", "share", "of", "the", "approximately", "$21.8", "million", "of", "revenues", "generated", "by", "Pfizer", "s", "sale", "of", "taliglucerase", "alfa", "to", "the", "Ministry", "of", "Health", "of", "Brazil", "under", "the", "short", "term", "supply", "agreement", "during", "Pfizer", "s", "2010", "fiscal", "year.", "<tag2>", "In", "the", "clinical", "section", "of", "the", "CRL,", "the", "FDA", "requested", "additional", "data", "from", "our", "ongoing", "switchover", "trial", "and", "our", "long-term", "extension", "trial.", "<tag3>"], "wordsA": ["This", "income", "resulted", "primarily", "from", "our", "share", "of", "the", "approximately", "$21.8", "million", "of", "revenues", "generated", "by", "Pfizer", "s", "sale", "of", "taliglucerase", "alfa", "to", "the", "Ministry", "of", "Health", "of", "Brazil", "under", "the", "short", "term", "supply", "agreement", "during", "Pfizer", "s", "2010", "fiscal", "year."], "wordsB": ["In", "the", "clinical", "section", "of", "the", "CRL,", "the", "FDA", "requested", "additional", "data", "from", "our", "ongoing", "switchover", "trial", "and", "our", "long-term", "extension", "trial."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p3_s1", "idA": "1006281_11_item7_p45_s2", "sentA": "No share in the collaboration was recorded for the year ended December 31, 2009.", "sentB": "The FDA did not request additional clinical studies in the CRL.", "type": 1, "words": ["<tag1>", "No", "share", "in", "the", "collaboration", "was", "recorded", "for", "the", "year", "ended", "December", "31,", "2009.", "<tag2>", "The", "FDA", "did", "not", "request", "additional", "clinical", "studies", "in", "the", "CRL.", "<tag3>"], "wordsA": ["No", "share", "in", "the", "collaboration", "was", "recorded", "for", "the", "year", "ended", "December", "31,", "2009."], "wordsB": ["The", "FDA", "did", "not", "request", "additional", "clinical", "studies", "in", "the", "CRL."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p22_s1", "idA": "1006281_11_item7_p65_s0", "sentA": "In connection with such funding, warrants to purchase an additional 8,862,803 Series C Preferred Shares were granted to the investors for no additional consideration with a total exercise price equal to $9.0 million.", "sentB": "According to public reports by Sanofi, consolidated sales of Cerezyme were 441.0 million (or $579.6 million), a growth of 11.1% compared to the same period in 2010.", "type": 1, "words": ["<tag1>", "In", "connection", "with", "such", "funding,", "warrants", "to", "purchase", "an", "additional", "8,862,803", "Series", "C", "Preferred", "Shares", "were", "granted", "to", "the", "investors", "for", "no", "additional", "consideration", "with", "a", "total", "exercise", "price", "equal", "to", "$9.0", "million.", "<tag2>", "According", "to", "public", "reports", "by", "Sanofi,", "consolidated", "sales", "of", "Cerezyme", "were", "441.0", "million", "(or", "$579.6", "million),", "a", "growth", "of", "11.1%", "compared", "to", "the", "same", "period", "in", "2010.", "<tag3>"], "wordsA": ["In", "connection", "with", "such", "funding,", "warrants", "to", "purchase", "an", "additional", "8,862,803", "Series", "C", "Preferred", "Shares", "were", "granted", "to", "the", "investors", "for", "no", "additional", "consideration", "with", "a", "total", "exercise", "price", "equal", "to", "$9.0", "million."], "wordsB": ["According", "to", "public", "reports", "by", "Sanofi,", "consolidated", "sales", "of", "Cerezyme", "were", "441.0", "million", "(or", "$579.6", "million),", "a", "growth", "of", "11.1%", "compared", "to", "the", "same", "period", "in", "2010."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p2_s3", "idA": "1006281_11_item7_p71_s2", "sentA": "We expect to incur significant research and development expenses, including expenses related to the hiring of personnel and the advancement of our additional pipeline of product candidate into the various clinical trials.", "sentB": "The main questions raised by the FDA regarding the NDA related to the clinical and CMC sections.", "type": 1, "words": ["<tag1>", "We", "expect", "to", "incur", "significant", "research", "and", "development", "expenses,", "including", "expenses", "related", "to", "the", "hiring", "of", "personnel", "and", "the", "advancement", "of", "our", "additional", "pipeline", "of", "product", "candidate", "into", "the", "various", "clinical", "trials.", "<tag2>", "The", "main", "questions", "raised", "by", "the", "FDA", "regarding", "the", "NDA", "related", "to", "the", "clinical", "and", "CMC", "sections.", "<tag3>"], "wordsA": ["We", "expect", "to", "incur", "significant", "research", "and", "development", "expenses,", "including", "expenses", "related", "to", "the", "hiring", "of", "personnel", "and", "the", "advancement", "of", "our", "additional", "pipeline", "of", "product", "candidate", "into", "the", "various", "clinical", "trials."], "wordsB": ["The", "main", "questions", "raised", "by", "the", "FDA", "regarding", "the", "NDA", "related", "to", "the", "clinical", "and", "CMC", "sections."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p21_s2", "idA": "1006281_11_item7_p72_s0", "sentA": "We believe that our existing cash and cash equivalents and the regulatory milestone payments we anticipate receiving from Pfizer will be sufficient to enable us to fund our operating expenses and capital expenditure requirements at least for the next 12 months.", "sentB": "If and when such vials are replaced, revenues will be recorded upon the supply of such replaced vials, and if it is determined that there is no longer a need for the replacement of vials, the allowance will be reversed and the revenues will be recognized accordingly.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "our", "existing", "cash", "and", "cash", "equivalents", "and", "the", "regulatory", "milestone", "payments", "we", "anticipate", "receiving", "from", "Pfizer", "will", "be", "sufficient", "to", "enable", "us", "to", "fund", "our", "operating", "expenses", "and", "capital", "expenditure", "requirements", "at", "least", "for", "the", "next", "12", "months.", "<tag2>", "If", "and", "when", "such", "vials", "are", "replaced,", "revenues", "will", "be", "recorded", "upon", "the", "supply", "of", "such", "replaced", "vials,", "and", "if", "it", "is", "determined", "that", "there", "is", "no", "longer", "a", "need", "for", "the", "replacement", "of", "vials,", "the", "allowance", "will", "be", "reversed", "and", "the", "revenues", "will", "be", "recognized", "accordingly.", "<tag3>"], "wordsA": ["We", "believe", "that", "our", "existing", "cash", "and", "cash", "equivalents", "and", "the", "regulatory", "milestone", "payments", "we", "anticipate", "receiving", "from", "Pfizer", "will", "be", "sufficient", "to", "enable", "us", "to", "fund", "our", "operating", "expenses", "and", "capital", "expenditure", "requirements", "at", "least", "for", "the", "next", "12", "months."], "wordsB": ["If", "and", "when", "such", "vials", "are", "replaced,", "revenues", "will", "be", "recorded", "upon", "the", "supply", "of", "such", "replaced", "vials,", "and", "if", "it", "is", "determined", "that", "there", "is", "no", "longer", "a", "need", "for", "the", "replacement", "of", "vials,", "the", "allowance", "will", "be", "reversed", "and", "the", "revenues", "will", "be", "recognized", "accordingly."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_12_item7_p3_s0", "idA": "1006281_11_item7_p9_s0", "sentA": "In December 2010 we held a pre-IND meeting with the FDA with respect to PRX-102.", "sentB": "In the CMC section of the CRL, the FDA requested information regarding testing specifications and assay validation.", "type": 1, "words": ["<tag1>", "In", "December", "2010", "we", "held", "a", "pre-IND", "meeting", "with", "the", "FDA", "with", "respect", "to", "PRX-102.", "<tag2>", "In", "the", "CMC", "section", "of", "the", "CRL,", "the", "FDA", "requested", "information", "regarding", "testing", "specifications", "and", "assay", "validation.", "<tag3>"], "wordsA": ["In", "December", "2010", "we", "held", "a", "pre-IND", "meeting", "with", "the", "FDA", "with", "respect", "to", "PRX-102."], "wordsB": ["In", "the", "CMC", "section", "of", "the", "CRL,", "the", "FDA", "requested", "information", "regarding", "testing", "specifications", "and", "assay", "validation."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_13_item7_p16_s1", "idA": "1006281_12_item7_p28_s3", "sentA": "We are also conducting pre clinical trials of our orally-administrated glucocerebrosidase enzyme for the treatment of Gaucher disease in small and large animals.", "sentB": "We anticipate commencing a clinical trial in Gaucher patients designed to demonstrate safety and achieve the first ever proof in concept regarding orally-administrated glucocerebrosidase enzyme during the first half of 2013.", "type": 1, "words": ["<tag1>", "We", "are", "also", "conducting", "pre", "clinical", "trials", "of", "our", "orally-administrated", "glucocerebrosidase", "enzyme", "for", "the", "treatment", "of", "Gaucher", "disease", "in", "small", "and", "large", "animals.", "<tag2>", "We", "anticipate", "commencing", "a", "clinical", "trial", "in", "Gaucher", "patients", "designed", "to", "demonstrate", "safety", "and", "achieve", "the", "first", "ever", "proof", "in", "concept", "regarding", "orally-administrated", "glucocerebrosidase", "enzyme", "during", "the", "first", "half", "of", "2013.", "<tag3>"], "wordsA": ["We", "are", "also", "conducting", "pre", "clinical", "trials", "of", "our", "orally-administrated", "glucocerebrosidase", "enzyme", "for", "the", "treatment", "of", "Gaucher", "disease", "in", "small", "and", "large", "animals."], "wordsB": ["We", "anticipate", "commencing", "a", "clinical", "trial", "in", "Gaucher", "patients", "designed", "to", "demonstrate", "safety", "and", "achieve", "the", "first", "ever", "proof", "in", "concept", "regarding", "orally-administrated", "glucocerebrosidase", "enzyme", "during", "the", "first", "half", "of", "2013."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_13_item7_p5_s0", "idA": "1006281_12_item7_p30_s1", "sentA": "Our pr-antiTNF product candidate has an amino acid sequence that is similar to Enbrel which is one of the treatments for patients of those diseases.", "sentB": "Gaucher patients suffer from mutations in or deficiencies of GCD, an enzyme that is naturally found in human cells.", "type": 1, "words": ["<tag1>", "Our", "pr-antiTNF", "product", "candidate", "has", "an", "amino", "acid", "sequence", "that", "is", "similar", "to", "Enbrel", "which", "is", "one", "of", "the", "treatments", "for", "patients", "of", "those", "diseases.", "<tag2>", "Gaucher", "patients", "suffer", "from", "mutations", "in", "or", "deficiencies", "of", "GCD,", "an", "enzyme", "that", "is", "naturally", "found", "in", "human", "cells.", "<tag3>"], "wordsA": ["Our", "pr-antiTNF", "product", "candidate", "has", "an", "amino", "acid", "sequence", "that", "is", "similar", "to", "Enbrel", "which", "is", "one", "of", "the", "treatments", "for", "patients", "of", "those", "diseases."], "wordsB": ["Gaucher", "patients", "suffer", "from", "mutations", "in", "or", "deficiencies", "of", "GCD,", "an", "enzyme", "that", "is", "naturally", "found", "in", "human", "cells."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_13_item7_p3_s0", "idA": "1006281_12_item7_p33_s5", "sentA": "However, if taliglucerase alfa is launched successfully, we anticipate that we will generate revenues to offset any such losses.", "sentB": "Taliglucerase alfa is a proprietary, recombinant form of glucocerebrosidase (GCD) that is expressed or produced through ProCellEx.", "type": 1, "words": ["<tag1>", "However,", "if", "taliglucerase", "alfa", "is", "launched", "successfully,", "we", "anticipate", "that", "we", "will", "generate", "revenues", "to", "offset", "any", "such", "losses.", "<tag2>", "Taliglucerase", "alfa", "is", "a", "proprietary,", "recombinant", "form", "of", "glucocerebrosidase", "(GCD)", "that", "is", "expressed", "or", "produced", "through", "ProCellEx.", "<tag3>"], "wordsA": ["However,", "if", "taliglucerase", "alfa", "is", "launched", "successfully,", "we", "anticipate", "that", "we", "will", "generate", "revenues", "to", "offset", "any", "such", "losses."], "wordsB": ["Taliglucerase", "alfa", "is", "a", "proprietary,", "recombinant", "form", "of", "glucocerebrosidase", "(GCD)", "that", "is", "expressed", "or", "produced", "through", "ProCellEx."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_13_item7_p8_s4", "idA": "1006281_12_item7_p51_s3", "sentA": "In addition, during 2010, we submitted a marketing application regarding taliglucerase alfa to the Israeli MOH and similar applications have been submitted to each of the EMA, ANVISA and the Australian TGA.", "sentB": "The milestones were achieved prior to the end of fiscal year 2012 and have been paid in full.", "type": 1, "words": ["<tag1>", "In", "addition,", "during", "2010,", "we", "submitted", "a", "marketing", "application", "regarding", "taliglucerase", "alfa", "to", "the", "Israeli", "MOH", "and", "similar", "applications", "have", "been", "submitted", "to", "each", "of", "the", "EMA,", "ANVISA", "and", "the", "Australian", "TGA.", "<tag2>", "The", "milestones", "were", "achieved", "prior", "to", "the", "end", "of", "fiscal", "year", "2012", "and", "have", "been", "paid", "in", "full.", "<tag3>"], "wordsA": ["In", "addition,", "during", "2010,", "we", "submitted", "a", "marketing", "application", "regarding", "taliglucerase", "alfa", "to", "the", "Israeli", "MOH", "and", "similar", "applications", "have", "been", "submitted", "to", "each", "of", "the", "EMA,", "ANVISA", "and", "the", "Australian", "TGA."], "wordsB": ["The", "milestones", "were", "achieved", "prior", "to", "the", "end", "of", "fiscal", "year", "2012", "and", "have", "been", "paid", "in", "full."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_14_item7_p24_s2", "idA": "1006281_13_item7_p11_s0", "sentA": "Currently, patients are being treated with ELELYSO on a commercial basis in the United States and in Israel shortly.", "sentB": "Amounts collected from customers and remitted to governmental authorities, which represents value-added taxes related to ELELYSO sales in Israel, are presented on a net basis in our Consolidated Statements of Operations, in that taxes billed to customers are not included as a component of net product revenues.", "type": 1, "words": ["<tag1>", "Currently,", "patients", "are", "being", "treated", "with", "ELELYSO", "on", "a", "commercial", "basis", "in", "the", "United", "States", "and", "in", "Israel", "shortly.", "<tag2>", "Amounts", "collected", "from", "customers", "and", "remitted", "to", "governmental", "authorities,", "which", "represents", "value-added", "taxes", "related", "to", "ELELYSO", "sales", "in", "Israel,", "are", "presented", "on", "a", "net", "basis", "in", "our", "Consolidated", "Statements", "of", "Operations,", "in", "that", "taxes", "billed", "to", "customers", "are", "not", "included", "as", "a", "component", "of", "net", "product", "revenues.", "<tag3>"], "wordsA": ["Currently,", "patients", "are", "being", "treated", "with", "ELELYSO", "on", "a", "commercial", "basis", "in", "the", "United", "States", "and", "in", "Israel", "shortly."], "wordsB": ["Amounts", "collected", "from", "customers", "and", "remitted", "to", "governmental", "authorities,", "which", "represents", "value-added", "taxes", "related", "to", "ELELYSO", "sales", "in", "Israel,", "are", "presented", "on", "a", "net", "basis", "in", "our", "Consolidated", "Statements", "of", "Operations,", "in", "that", "taxes", "billed", "to", "customers", "are", "not", "included", "as", "a", "component", "of", "net", "product", "revenues."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_14_item7_p8_s1", "idA": "1006281_13_item7_p24_s1", "sentA": "We recognize revenue when the earnings process is complete, which is when revenue is realized or realizable and earned, there is persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable and collectability is reasonably assured.", "sentB": "The agreement became effective in January 2014.", "type": 1, "words": ["<tag1>", "We", "recognize", "revenue", "when", "the", "earnings", "process", "is", "complete,", "which", "is", "when", "revenue", "is", "realized", "or", "realizable", "and", "earned,", "there", "is", "persuasive", "evidence", "a", "revenue", "arrangement", "exists,", "delivery", "of", "goods", "or", "services", "has", "occurred,", "the", "sales", "price", "is", "fixed", "or", "determinable", "and", "collectability", "is", "reasonably", "assured.", "<tag2>", "The", "agreement", "became", "effective", "in", "January", "2014.", "<tag3>"], "wordsA": ["We", "recognize", "revenue", "when", "the", "earnings", "process", "is", "complete,", "which", "is", "when", "revenue", "is", "realized", "or", "realizable", "and", "earned,", "there", "is", "persuasive", "evidence", "a", "revenue", "arrangement", "exists,", "delivery", "of", "goods", "or", "services", "has", "occurred,", "the", "sales", "price", "is", "fixed", "or", "determinable", "and", "collectability", "is", "reasonably", "assured."], "wordsB": ["The", "agreement", "became", "effective", "in", "January", "2014."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_14_item7_p12_s4", "idA": "1006281_13_item7_p28_s1", "sentA": "The revenues represent our cost with respect to the product sold.", "sentB": "Based on the data from this study, an application for a supplement to the NDA for ELEYSO, allowing a pediatric use indication to be added to the product label, has recently been submitted by Pfizer to the FDA.", "type": 1, "words": ["<tag1>", "The", "revenues", "represent", "our", "cost", "with", "respect", "to", "the", "product", "sold.", "<tag2>", "Based", "on", "the", "data", "from", "this", "study,", "an", "application", "for", "a", "supplement", "to", "the", "NDA", "for", "ELEYSO,", "allowing", "a", "pediatric", "use", "indication", "to", "be", "added", "to", "the", "product", "label,", "has", "recently", "been", "submitted", "by", "Pfizer", "to", "the", "FDA.", "<tag3>"], "wordsA": ["The", "revenues", "represent", "our", "cost", "with", "respect", "to", "the", "product", "sold."], "wordsB": ["Based", "on", "the", "data", "from", "this", "study,", "an", "application", "for", "a", "supplement", "to", "the", "NDA", "for", "ELEYSO,", "allowing", "a", "pediatric", "use", "indication", "to", "be", "added", "to", "the", "product", "label,", "has", "recently", "been", "submitted", "by", "Pfizer", "to", "the", "FDA."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_14_item7_p24_s1", "idA": "1006281_13_item7_p33_s1", "sentA": "Each grant is deducted from the related research and development expenses as the costs are incurred.", "sentB": "Product sale transactions are evidenced by customer purchase orders, customer contracts, invoices and/or the related shipping documents.", "type": 1, "words": ["<tag1>", "Each", "grant", "is", "deducted", "from", "the", "related", "research", "and", "development", "expenses", "as", "the", "costs", "are", "incurred.", "<tag2>", "Product", "sale", "transactions", "are", "evidenced", "by", "customer", "purchase", "orders,", "customer", "contracts,", "invoices", "and/or", "the", "related", "shipping", "documents.", "<tag3>"], "wordsA": ["Each", "grant", "is", "deducted", "from", "the", "related", "research", "and", "development", "expenses", "as", "the", "costs", "are", "incurred."], "wordsB": ["Product", "sale", "transactions", "are", "evidenced", "by", "customer", "purchase", "orders,", "customer", "contracts,", "invoices", "and/or", "the", "related", "shipping", "documents."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item7_p20_s1", "idA": "1006281_14_item7_p15_s1", "sentA": "We have built an internal marketing team designed to serve the Israeli market for taliglucerase alfa and we intend to establish internal commercialization and marketing teams for our other product candidates in North America, the European Union and in other significant markets, including Israel, subject to required marketing approvals, as the need arises.", "sentB": "PRX-102 has been the subject of successful proof of concept clinical trials, as described in Item 1, and we intend to focus our efforts on a new formulation of the treatment during 2015.", "type": 1, "words": ["<tag1>", "We", "have", "built", "an", "internal", "marketing", "team", "designed", "to", "serve", "the", "Israeli", "market", "for", "taliglucerase", "alfa", "and", "we", "intend", "to", "establish", "internal", "commercialization", "and", "marketing", "teams", "for", "our", "other", "product", "candidates", "in", "North", "America,", "the", "European", "Union", "and", "in", "other", "significant", "markets,", "including", "Israel,", "subject", "to", "required", "marketing", "approvals,", "as", "the", "need", "arises.", "<tag2>", "PRX-102", "has", "been", "the", "subject", "of", "successful", "proof", "of", "concept", "clinical", "trials,", "as", "described", "in", "Item", "1,", "and", "we", "intend", "to", "focus", "our", "efforts", "on", "a", "new", "formulation", "of", "the", "treatment", "during", "2015.", "<tag3>"], "wordsA": ["We", "have", "built", "an", "internal", "marketing", "team", "designed", "to", "serve", "the", "Israeli", "market", "for", "taliglucerase", "alfa", "and", "we", "intend", "to", "establish", "internal", "commercialization", "and", "marketing", "teams", "for", "our", "other", "product", "candidates", "in", "North", "America,", "the", "European", "Union", "and", "in", "other", "significant", "markets,", "including", "Israel,", "subject", "to", "required", "marketing", "approvals,", "as", "the", "need", "arises."], "wordsB": ["PRX-102", "has", "been", "the", "subject", "of", "successful", "proof", "of", "concept", "clinical", "trials,", "as", "described", "in", "Item", "1,", "and", "we", "intend", "to", "focus", "our", "efforts", "on", "a", "new", "formulation", "of", "the", "treatment", "during", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item7_p4_s0", "idA": "1006281_14_item7_p3_s1", "sentA": "Subsequently, taliglucerase alfa was approved by ANVISA in March 2013, by the Israeli MOH in September 2012, and by the applicable regulatory authorities in Uruguay, Mexico and Chile.", "sentB": "In August 2014, the FDA approved Elelyso for injection for pediatric patients and the Israeli MOH approved the pediatric indication in January 2015.", "type": 1, "words": ["<tag1>", "Subsequently,", "taliglucerase", "alfa", "was", "approved", "by", "ANVISA", "in", "March", "2013,", "by", "the", "Israeli", "MOH", "in", "September", "2012,", "and", "by", "the", "applicable", "regulatory", "authorities", "in", "Uruguay,", "Mexico", "and", "Chile.", "<tag2>", "In", "August", "2014,", "the", "FDA", "approved", "Elelyso", "for", "injection", "for", "pediatric", "patients", "and", "the", "Israeli", "MOH", "approved", "the", "pediatric", "indication", "in", "January", "2015.", "<tag3>"], "wordsA": ["Subsequently,", "taliglucerase", "alfa", "was", "approved", "by", "ANVISA", "in", "March", "2013,", "by", "the", "Israeli", "MOH", "in", "September", "2012,", "and", "by", "the", "applicable", "regulatory", "authorities", "in", "Uruguay,", "Mexico", "and", "Chile."], "wordsB": ["In", "August", "2014,", "the", "FDA", "approved", "Elelyso", "for", "injection", "for", "pediatric", "patients", "and", "the", "Israeli", "MOH", "approved", "the", "pediatric", "indication", "in", "January", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_15_item7_p17_s1", "idA": "1006281_14_item7_p69_s0", "sentA": "We expect to continue to incur significant expenditures in the near future.", "sentB": "We expect to report interim efficacy and safety results for the 1 mg/kg dose group of the trial during the third quarter of 2015 and to report final efficacy and safety results for the 0.2mg, 1 mg and 2mg/kg dose groups of the trial during the fourth quarter of 2015.", "type": 1, "words": ["<tag1>", "We", "expect", "to", "continue", "to", "incur", "significant", "expenditures", "in", "the", "near", "future.", "<tag2>", "We", "expect", "to", "report", "interim", "efficacy", "and", "safety", "results", "for", "the", "1", "mg/kg", "dose", "group", "of", "the", "trial", "during", "the", "third", "quarter", "of", "2015", "and", "to", "report", "final", "efficacy", "and", "safety", "results", "for", "the", "0.2mg,", "1", "mg", "and", "2mg/kg", "dose", "groups", "of", "the", "trial", "during", "the", "fourth", "quarter", "of", "2015.", "<tag3>"], "wordsA": ["We", "expect", "to", "continue", "to", "incur", "significant", "expenditures", "in", "the", "near", "future."], "wordsB": ["We", "expect", "to", "report", "interim", "efficacy", "and", "safety", "results", "for", "the", "1", "mg/kg", "dose", "group", "of", "the", "trial", "during", "the", "third", "quarter", "of", "2015", "and", "to", "report", "final", "efficacy", "and", "safety", "results", "for", "the", "0.2mg,", "1", "mg", "and", "2mg/kg", "dose", "groups", "of", "the", "trial", "during", "the", "fourth", "quarter", "of", "2015."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item7_p4_s1", "idA": "1006281_15_item7_p27_s2", "sentA": "We recognize our share of net profit or loss under the Pfizer Agreement based on reports we receive from Pfizer summarizing the results of the collaborative activities under the agreement for the applicable period.", "sentB": "The Amended Pfizer Agreement also includes provisions regarding cooperation for regulatory matters, supply of the drug substance to Pfizer, including provisions addressing failure to supply, and patent enforcement, and contains customary provisions regarding termination, indemnification and insurance requirements.", "type": 1, "words": ["<tag1>", "We", "recognize", "our", "share", "of", "net", "profit", "or", "loss", "under", "the", "Pfizer", "Agreement", "based", "on", "reports", "we", "receive", "from", "Pfizer", "summarizing", "the", "results", "of", "the", "collaborative", "activities", "under", "the", "agreement", "for", "the", "applicable", "period.", "<tag2>", "The", "Amended", "Pfizer", "Agreement", "also", "includes", "provisions", "regarding", "cooperation", "for", "regulatory", "matters,", "supply", "of", "the", "drug", "substance", "to", "Pfizer,", "including", "provisions", "addressing", "failure", "to", "supply,", "and", "patent", "enforcement,", "and", "contains", "customary", "provisions", "regarding", "termination,", "indemnification", "and", "insurance", "requirements.", "<tag3>"], "wordsA": ["We", "recognize", "our", "share", "of", "net", "profit", "or", "loss", "under", "the", "Pfizer", "Agreement", "based", "on", "reports", "we", "receive", "from", "Pfizer", "summarizing", "the", "results", "of", "the", "collaborative", "activities", "under", "the", "agreement", "for", "the", "applicable", "period."], "wordsB": ["The", "Amended", "Pfizer", "Agreement", "also", "includes", "provisions", "regarding", "cooperation", "for", "regulatory", "matters,", "supply", "of", "the", "drug", "substance", "to", "Pfizer,", "including", "provisions", "addressing", "failure", "to", "supply,", "and", "patent", "enforcement,", "and", "contains", "customary", "provisions", "regarding", "termination,", "indemnification", "and", "insurance", "requirements."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item7_p6_s3", "idA": "1006281_15_item7_p39_s0", "sentA": "We expect our research and development expenses to continue to be our primary expense in the future as we continue the advancement of our clinical trials and preclinical product development programs for our product candidates.", "sentB": "We are discussing with Fiocruz potential actions that Fiocruz may take to comply with its purchase obligations and, based on such discussions, we will determine what we believe to be the course of action that is in the best interest of our company.", "type": 1, "words": ["<tag1>", "We", "expect", "our", "research", "and", "development", "expenses", "to", "continue", "to", "be", "our", "primary", "expense", "in", "the", "future", "as", "we", "continue", "the", "advancement", "of", "our", "clinical", "trials", "and", "preclinical", "product", "development", "programs", "for", "our", "product", "candidates.", "<tag2>", "We", "are", "discussing", "with", "Fiocruz", "potential", "actions", "that", "Fiocruz", "may", "take", "to", "comply", "with", "its", "purchase", "obligations", "and,", "based", "on", "such", "discussions,", "we", "will", "determine", "what", "we", "believe", "to", "be", "the", "course", "of", "action", "that", "is", "in", "the", "best", "interest", "of", "our", "company.", "<tag3>"], "wordsA": ["We", "expect", "our", "research", "and", "development", "expenses", "to", "continue", "to", "be", "our", "primary", "expense", "in", "the", "future", "as", "we", "continue", "the", "advancement", "of", "our", "clinical", "trials", "and", "preclinical", "product", "development", "programs", "for", "our", "product", "candidates."], "wordsB": ["We", "are", "discussing", "with", "Fiocruz", "potential", "actions", "that", "Fiocruz", "may", "take", "to", "comply", "with", "its", "purchase", "obligations", "and,", "based", "on", "such", "discussions,", "we", "will", "determine", "what", "we", "believe", "to", "be", "the", "course", "of", "action", "that", "is", "in", "the", "best", "interest", "of", "our", "company."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_16_item7_p10_s1", "idA": "1006281_15_item7_p75_s0", "sentA": "We expect to continue to incur significant expenditures in the near future.", "sentB": "We concluded the phase I clinical trial, which demonstrated that the drug was safe and well tolerated, showing biological activity in the gut and inducement of regulatory T cells .", "type": 1, "words": ["<tag1>", "We", "expect", "to", "continue", "to", "incur", "significant", "expenditures", "in", "the", "near", "future.", "<tag2>", "We", "concluded", "the", "phase", "I", "clinical", "trial,", "which", "demonstrated", "that", "the", "drug", "was", "safe", "and", "well", "tolerated,", "showing", "biological", "activity", "in", "the", "gut", "and", "inducement", "of", "regulatory", "T", "cells", ".", "<tag3>"], "wordsA": ["We", "expect", "to", "continue", "to", "incur", "significant", "expenditures", "in", "the", "near", "future."], "wordsB": ["We", "concluded", "the", "phase", "I", "clinical", "trial,", "which", "demonstrated", "that", "the", "drug", "was", "safe", "and", "well", "tolerated,", "showing", "biological", "activity", "in", "the", "gut", "and", "inducement", "of", "regulatory", "T", "cells", "."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item7_p8_s2", "idA": "1006281_16_item7_p12_s0", "sentA": "Our significant accounting policies are more fully described in Note 1 to our consolidated financial statements appearing at the end of this Annual Report on Form 10-K. We believe that the accounting policies below are critical for one to fully understand and evaluate our financial condition and results of operations.", "sentB": "Shipments are to start in mid-2017 and continue through the end of the year, in increasing volumes.", "type": 1, "words": ["<tag1>", "Our", "significant", "accounting", "policies", "are", "more", "fully", "described", "in", "Note", "1", "to", "our", "consolidated", "financial", "statements", "appearing", "at", "the", "end", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "We", "believe", "that", "the", "accounting", "policies", "below", "are", "critical", "for", "one", "to", "fully", "understand", "and", "evaluate", "our", "financial", "condition", "and", "results", "of", "operations.", "<tag2>", "Shipments", "are", "to", "start", "in", "mid-2017", "and", "continue", "through", "the", "end", "of", "the", "year,", "in", "increasing", "volumes.", "<tag3>"], "wordsA": ["Our", "significant", "accounting", "policies", "are", "more", "fully", "described", "in", "Note", "1", "to", "our", "consolidated", "financial", "statements", "appearing", "at", "the", "end", "of", "this", "Annual", "Report", "on", "Form", "10-K.", "We", "believe", "that", "the", "accounting", "policies", "below", "are", "critical", "for", "one", "to", "fully", "understand", "and", "evaluate", "our", "financial", "condition", "and", "results", "of", "operations."], "wordsB": ["Shipments", "are", "to", "start", "in", "mid-2017", "and", "continue", "through", "the", "end", "of", "the", "year,", "in", "increasing", "volumes."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item7_p11_s1", "idA": "1006281_16_item7_p19_s0", "sentA": "We recognize revenues received from the sale of a product when the sales price is fixed or determinable and collectability is reasonably assured.", "sentB": "alidornase alfa is currently the subject of a phase II efficacy and safety study.", "type": 1, "words": ["<tag1>", "We", "recognize", "revenues", "received", "from", "the", "sale", "of", "a", "product", "when", "the", "sales", "price", "is", "fixed", "or", "determinable", "and", "collectability", "is", "reasonably", "assured.", "<tag2>", "alidornase", "alfa", "is", "currently", "the", "subject", "of", "a", "phase", "II", "efficacy", "and", "safety", "study.", "<tag3>"], "wordsA": ["We", "recognize", "revenues", "received", "from", "the", "sale", "of", "a", "product", "when", "the", "sales", "price", "is", "fixed", "or", "determinable", "and", "collectability", "is", "reasonably", "assured."], "wordsB": ["alidornase", "alfa", "is", "currently", "the", "subject", "of", "a", "phase", "II", "efficacy", "and", "safety", "study."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item7_p46_s1", "idA": "1006281_16_item7_p46_s0", "sentA": "The guidance requires the use of a risk free interest rate based on the implied yield currently available on zero coupon government issues of the country in whose currency the exercise price is expressed, with a remaining term equal to the expected life of the option being valued.", "sentB": "ASC 470-20 regarding debt with conversion and other options requires the issuer of a convertible debt instrument that may be settled in cash upon conversion to separately account for the liability (debt) and equity (conversion option) components of the instrument in a manner that reflects the issuer s nonconvertible debt borrowing rate.", "type": 1, "words": ["<tag1>", "The", "guidance", "requires", "the", "use", "of", "a", "risk", "free", "interest", "rate", "based", "on", "the", "implied", "yield", "currently", "available", "on", "zero", "coupon", "government", "issues", "of", "the", "country", "in", "whose", "currency", "the", "exercise", "price", "is", "expressed,", "with", "a", "remaining", "term", "equal", "to", "the", "expected", "life", "of", "the", "option", "being", "valued.", "<tag2>", "ASC", "470-20", "regarding", "debt", "with", "conversion", "and", "other", "options", "requires", "the", "issuer", "of", "a", "convertible", "debt", "instrument", "that", "may", "be", "settled", "in", "cash", "upon", "conversion", "to", "separately", "account", "for", "the", "liability", "(debt)", "and", "equity", "(conversion", "option)", "components", "of", "the", "instrument", "in", "a", "manner", "that", "reflects", "the", "issuer", "s", "nonconvertible", "debt", "borrowing", "rate.", "<tag3>"], "wordsA": ["The", "guidance", "requires", "the", "use", "of", "a", "risk", "free", "interest", "rate", "based", "on", "the", "implied", "yield", "currently", "available", "on", "zero", "coupon", "government", "issues", "of", "the", "country", "in", "whose", "currency", "the", "exercise", "price", "is", "expressed,", "with", "a", "remaining", "term", "equal", "to", "the", "expected", "life", "of", "the", "option", "being", "valued."], "wordsB": ["ASC", "470-20", "regarding", "debt", "with", "conversion", "and", "other", "options", "requires", "the", "issuer", "of", "a", "convertible", "debt", "instrument", "that", "may", "be", "settled", "in", "cash", "upon", "conversion", "to", "separately", "account", "for", "the", "liability", "(debt)", "and", "equity", "(conversion", "option)", "components", "of", "the", "instrument", "in", "a", "manner", "that", "reflects", "the", "issuer", "s", "nonconvertible", "debt", "borrowing", "rate."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item7_p46_s0", "idA": "1006281_16_item7_p5_s0", "sentA": "On October 12, 2015, we also entered into a Stock Purchase Agreement with Pfizer pursuant to which we issued 5,649,079 shares of our common stock for an aggregate purchase price equal to $10.0 million subject to certain other terms set forth in the Stock Purchase Agreement.", "sentB": "All outstanding convertible notes are accounted for using the guidance set forth in the Financial Accounting Standards Board, or FASB, Accounting Standards Codification (ASC) 815 requiring that we determine whether the embedded conversion option must be separated and accounted for separately.", "type": 1, "words": ["<tag1>", "On", "October", "12,", "2015,", "we", "also", "entered", "into", "a", "Stock", "Purchase", "Agreement", "with", "Pfizer", "pursuant", "to", "which", "we", "issued", "5,649,079", "shares", "of", "our", "common", "stock", "for", "an", "aggregate", "purchase", "price", "equal", "to", "$10.0", "million", "subject", "to", "certain", "other", "terms", "set", "forth", "in", "the", "Stock", "Purchase", "Agreement.", "<tag2>", "All", "outstanding", "convertible", "notes", "are", "accounted", "for", "using", "the", "guidance", "set", "forth", "in", "the", "Financial", "Accounting", "Standards", "Board,", "or", "FASB,", "Accounting", "Standards", "Codification", "(ASC)", "815", "requiring", "that", "we", "determine", "whether", "the", "embedded", "conversion", "option", "must", "be", "separated", "and", "accounted", "for", "separately.", "<tag3>"], "wordsA": ["On", "October", "12,", "2015,", "we", "also", "entered", "into", "a", "Stock", "Purchase", "Agreement", "with", "Pfizer", "pursuant", "to", "which", "we", "issued", "5,649,079", "shares", "of", "our", "common", "stock", "for", "an", "aggregate", "purchase", "price", "equal", "to", "$10.0", "million", "subject", "to", "certain", "other", "terms", "set", "forth", "in", "the", "Stock", "Purchase", "Agreement."], "wordsB": ["All", "outstanding", "convertible", "notes", "are", "accounted", "for", "using", "the", "guidance", "set", "forth", "in", "the", "Financial", "Accounting", "Standards", "Board,", "or", "FASB,", "Accounting", "Standards", "Codification", "(ASC)", "815", "requiring", "that", "we", "determine", "whether", "the", "embedded", "conversion", "option", "must", "be", "separated", "and", "accounted", "for", "separately."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item7_p47_s0", "idA": "1006281_16_item7_p63_s3", "sentA": "Net cash provided by financing activities was $6.6 million and consisted primarily from the issuance of shares to Pfizer in connection with the sale of our share in collaboration to Pfizer.", "sentB": "The debt discount and debt issuance costs regarding the issuance of 4.5% convertible notes are deferred and amortized over the applicable convertible period (5 years).", "type": 1, "words": ["<tag1>", "Net", "cash", "provided", "by", "financing", "activities", "was", "$6.6", "million", "and", "consisted", "primarily", "from", "the", "issuance", "of", "shares", "to", "Pfizer", "in", "connection", "with", "the", "sale", "of", "our", "share", "in", "collaboration", "to", "Pfizer.", "<tag2>", "The", "debt", "discount", "and", "debt", "issuance", "costs", "regarding", "the", "issuance", "of", "4.5%", "convertible", "notes", "are", "deferred", "and", "amortized", "over", "the", "applicable", "convertible", "period", "(5", "years).", "<tag3>"], "wordsA": ["Net", "cash", "provided", "by", "financing", "activities", "was", "$6.6", "million", "and", "consisted", "primarily", "from", "the", "issuance", "of", "shares", "to", "Pfizer", "in", "connection", "with", "the", "sale", "of", "our", "share", "in", "collaboration", "to", "Pfizer."], "wordsB": ["The", "debt", "discount", "and", "debt", "issuance", "costs", "regarding", "the", "issuance", "of", "4.5%", "convertible", "notes", "are", "deferred", "and", "amortized", "over", "the", "applicable", "convertible", "period", "(5", "years)."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_17_item7_p48_s1", "idA": "1006281_16_item7_p65_s0", "sentA": "We believe that our existing cash and cash equivalents will be sufficient for at least 12 months.", "sentB": "Issuance costs that were allocated to liability will be amortized using the effective interest rate, other than issuance costs that were allocated to derivative, which were expensed immediately.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "our", "existing", "cash", "and", "cash", "equivalents", "will", "be", "sufficient", "for", "at", "least", "12", "months.", "<tag2>", "Issuance", "costs", "that", "were", "allocated", "to", "liability", "will", "be", "amortized", "using", "the", "effective", "interest", "rate,", "other", "than", "issuance", "costs", "that", "were", "allocated", "to", "derivative,", "which", "were", "expensed", "immediately.", "<tag3>"], "wordsA": ["We", "believe", "that", "our", "existing", "cash", "and", "cash", "equivalents", "will", "be", "sufficient", "for", "at", "least", "12", "months."], "wordsB": ["Issuance", "costs", "that", "were", "allocated", "to", "liability", "will", "be", "amortized", "using", "the", "effective", "interest", "rate,", "other", "than", "issuance", "costs", "that", "were", "allocated", "to", "derivative,", "which", "were", "expensed", "immediately."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p7_s0", "idA": "1006281_17_item7_p1_s0", "sentA": "We are a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on our proprietary ProCellEx system.", "sentB": "Fast Track designation is a process designed to facilitate the development and expedite the review of drugs and vaccines for serious conditions that fill an unmet medical need.", "type": 1, "words": ["<tag1>", "We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "and", "commercialization", "of", "recombinant", "therapeutic", "proteins", "based", "on", "our", "proprietary", "ProCellEx", "system.", "<tag2>", "Fast", "Track", "designation", "is", "a", "process", "designed", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drugs", "and", "vaccines", "for", "serious", "conditions", "that", "fill", "an", "unmet", "medical", "need.", "<tag3>"], "wordsA": ["We", "are", "a", "biopharmaceutical", "company", "focused", "on", "the", "development", "and", "commercialization", "of", "recombinant", "therapeutic", "proteins", "based", "on", "our", "proprietary", "ProCellEx", "system."], "wordsB": ["Fast", "Track", "designation", "is", "a", "process", "designed", "to", "facilitate", "the", "development", "and", "expedite", "the", "review", "of", "drugs", "and", "vaccines", "for", "serious", "conditions", "that", "fill", "an", "unmet", "medical", "need."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p23_s3", "idA": "1006281_17_item7_p29_s0", "sentA": "We anticipate incurring increasing costs in connection with the continued development of all of the product candidates in our pipeline.", "sentB": "We will recognize revenues after the commencement of drug supply over the period of the product s sales according to our best estimate of sale price.", "type": 1, "words": ["<tag1>", "We", "anticipate", "incurring", "increasing", "costs", "in", "connection", "with", "the", "continued", "development", "of", "all", "of", "the", "product", "candidates", "in", "our", "pipeline.", "<tag2>", "We", "will", "recognize", "revenues", "after", "the", "commencement", "of", "drug", "supply", "over", "the", "period", "of", "the", "product", "s", "sales", "according", "to", "our", "best", "estimate", "of", "sale", "price.", "<tag3>"], "wordsA": ["We", "anticipate", "incurring", "increasing", "costs", "in", "connection", "with", "the", "continued", "development", "of", "all", "of", "the", "product", "candidates", "in", "our", "pipeline."], "wordsB": ["We", "will", "recognize", "revenues", "after", "the", "commencement", "of", "drug", "supply", "over", "the", "period", "of", "the", "product", "s", "sales", "according", "to", "our", "best", "estimate", "of", "sale", "price."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p5_s1", "idA": "1006281_17_item7_p2_s1", "sentA": "Subsequently, taliglucerase alfa was approved for marketing by the regulatory authorities of other countries.", "sentB": "If the orphan drug designation is maintained at the time pegunigalsidase alfa is approved for marketing in the European Union, if at all, we expect that PRX-102 will benefit from 10 years of market exclusivity within the European Union.", "type": 1, "words": ["<tag1>", "Subsequently,", "taliglucerase", "alfa", "was", "approved", "for", "marketing", "by", "the", "regulatory", "authorities", "of", "other", "countries.", "<tag2>", "If", "the", "orphan", "drug", "designation", "is", "maintained", "at", "the", "time", "pegunigalsidase", "alfa", "is", "approved", "for", "marketing", "in", "the", "European", "Union,", "if", "at", "all,", "we", "expect", "that", "PRX-102", "will", "benefit", "from", "10", "years", "of", "market", "exclusivity", "within", "the", "European", "Union.", "<tag3>"], "wordsA": ["Subsequently,", "taliglucerase", "alfa", "was", "approved", "for", "marketing", "by", "the", "regulatory", "authorities", "of", "other", "countries."], "wordsB": ["If", "the", "orphan", "drug", "designation", "is", "maintained", "at", "the", "time", "pegunigalsidase", "alfa", "is", "approved", "for", "marketing", "in", "the", "European", "Union,", "if", "at", "all,", "we", "expect", "that", "PRX-102", "will", "benefit", "from", "10", "years", "of", "market", "exclusivity", "within", "the", "European", "Union."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p23_s0", "idA": "1006281_17_item7_p30_s1", "sentA": "Each grant is deducted from the related research and development expenses as the costs are incurred.", "sentB": "We also generate revenues from the Chiesi Agreement.", "type": 1, "words": ["<tag1>", "Each", "grant", "is", "deducted", "from", "the", "related", "research", "and", "development", "expenses", "as", "the", "costs", "are", "incurred.", "<tag2>", "We", "also", "generate", "revenues", "from", "the", "Chiesi", "Agreement.", "<tag3>"], "wordsA": ["Each", "grant", "is", "deducted", "from", "the", "related", "research", "and", "development", "expenses", "as", "the", "costs", "are", "incurred."], "wordsB": ["We", "also", "generate", "revenues", "from", "the", "Chiesi", "Agreement."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p23_s1", "idA": "1006281_17_item7_p42_s1", "sentA": "We do not have a dividend policy and given the lack of profitability, dividends are not expected in the foreseeable future, if at all.", "sentB": "As Chiesi is obligated to acquire pegunigalsidase alfa from us, and has limited, immaterial rights until then, the development services performed under the agreement are not considered to have a stand-alone value, and will be viewed as one unit of account - manufacturing and supply of the drug.", "type": 1, "words": ["<tag1>", "We", "do", "not", "have", "a", "dividend", "policy", "and", "given", "the", "lack", "of", "profitability,", "dividends", "are", "not", "expected", "in", "the", "foreseeable", "future,", "if", "at", "all.", "<tag2>", "As", "Chiesi", "is", "obligated", "to", "acquire", "pegunigalsidase", "alfa", "from", "us,", "and", "has", "limited,", "immaterial", "rights", "until", "then,", "the", "development", "services", "performed", "under", "the", "agreement", "are", "not", "considered", "to", "have", "a", "stand-alone", "value,", "and", "will", "be", "viewed", "as", "one", "unit", "of", "account", "-", "manufacturing", "and", "supply", "of", "the", "drug.", "<tag3>"], "wordsA": ["We", "do", "not", "have", "a", "dividend", "policy", "and", "given", "the", "lack", "of", "profitability,", "dividends", "are", "not", "expected", "in", "the", "foreseeable", "future,", "if", "at", "all."], "wordsB": ["As", "Chiesi", "is", "obligated", "to", "acquire", "pegunigalsidase", "alfa", "from", "us,", "and", "has", "limited,", "immaterial", "rights", "until", "then,", "the", "development", "services", "performed", "under", "the", "agreement", "are", "not", "considered", "to", "have", "a", "stand-alone", "value,", "and", "will", "be", "viewed", "as", "one", "unit", "of", "account", "-", "manufacturing", "and", "supply", "of", "the", "drug."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p3_s5", "idA": "1006281_17_item7_p50_s1", "sentA": "The increase is mainly due to cost of revenues that were attributed to an increase in the amount of drug substance sold to Pfizer at cost during the period and that a substantial portion of activities performed during 2015 were attributed to the development and production of PRX-102 for the entire period during which the phase III clinical trial is to be performed.", "sentB": "Chiesi is required to make tiered payments of 15% to 35% of its net sales, depending on the amount of annual sales, as consideration for the supply of pegunigalsidase alfa.", "type": 1, "words": ["<tag1>", "The", "increase", "is", "mainly", "due", "to", "cost", "of", "revenues", "that", "were", "attributed", "to", "an", "increase", "in", "the", "amount", "of", "drug", "substance", "sold", "to", "Pfizer", "at", "cost", "during", "the", "period", "and", "that", "a", "substantial", "portion", "of", "activities", "performed", "during", "2015", "were", "attributed", "to", "the", "development", "and", "production", "of", "PRX-102", "for", "the", "entire", "period", "during", "which", "the", "phase", "III", "clinical", "trial", "is", "to", "be", "performed.", "<tag2>", "Chiesi", "is", "required", "to", "make", "tiered", "payments", "of", "15%", "to", "35%", "of", "its", "net", "sales,", "depending", "on", "the", "amount", "of", "annual", "sales,", "as", "consideration", "for", "the", "supply", "of", "pegunigalsidase", "alfa.", "<tag3>"], "wordsA": ["The", "increase", "is", "mainly", "due", "to", "cost", "of", "revenues", "that", "were", "attributed", "to", "an", "increase", "in", "the", "amount", "of", "drug", "substance", "sold", "to", "Pfizer", "at", "cost", "during", "the", "period", "and", "that", "a", "substantial", "portion", "of", "activities", "performed", "during", "2015", "were", "attributed", "to", "the", "development", "and", "production", "of", "PRX-102", "for", "the", "entire", "period", "during", "which", "the", "phase", "III", "clinical", "trial", "is", "to", "be", "performed."], "wordsB": ["Chiesi", "is", "required", "to", "make", "tiered", "payments", "of", "15%", "to", "35%", "of", "its", "net", "sales,", "depending", "on", "the", "amount", "of", "annual", "sales,", "as", "consideration", "for", "the", "supply", "of", "pegunigalsidase", "alfa."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p4_s2", "idA": "1006281_17_item7_p61_s3", "sentA": "We believe that the funds currently available to us as are sufficient to satisfy our capital needs for at least 12 months.", "sentB": "The COMP cited clinical and non-clinical justifications we provided to establish the significant benefit of pegunigalsidase alfa, noting that the COMP considered the justifications to constitute a clinically relevant advantage.", "type": 1, "words": ["<tag1>", "We", "believe", "that", "the", "funds", "currently", "available", "to", "us", "as", "are", "sufficient", "to", "satisfy", "our", "capital", "needs", "for", "at", "least", "12", "months.", "<tag2>", "The", "COMP", "cited", "clinical", "and", "non-clinical", "justifications", "we", "provided", "to", "establish", "the", "significant", "benefit", "of", "pegunigalsidase", "alfa,", "noting", "that", "the", "COMP", "considered", "the", "justifications", "to", "constitute", "a", "clinically", "relevant", "advantage.", "<tag3>"], "wordsA": ["We", "believe", "that", "the", "funds", "currently", "available", "to", "us", "as", "are", "sufficient", "to", "satisfy", "our", "capital", "needs", "for", "at", "least", "12", "months."], "wordsB": ["The", "COMP", "cited", "clinical", "and", "non-clinical", "justifications", "we", "provided", "to", "establish", "the", "significant", "benefit", "of", "pegunigalsidase", "alfa,", "noting", "that", "the", "COMP", "considered", "the", "justifications", "to", "constitute", "a", "clinically", "relevant", "advantage."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p3_s3", "idA": "1006281_17_item7_p64_s0", "sentA": "Pfizer paid Protalix Ltd. $60.0 million as an upfront payment in connection with the execution of the Pfizer Agreement and subsequently paid to Protalix Ltd. an additional $5.0 million upon Protalix Ltd. s meeting a certain milestone.", "sentB": "Protalix Ltd. is also eligible to receive an additional up to $320 million, in the aggregate, in regulatory and commercial milestone payments.", "type": 1, "words": ["<tag1>", "Pfizer", "paid", "Protalix", "Ltd.", "$60.0", "million", "as", "an", "upfront", "payment", "in", "connection", "with", "the", "execution", "of", "the", "Pfizer", "Agreement", "and", "subsequently", "paid", "to", "Protalix", "Ltd.", "an", "additional", "$5.0", "million", "upon", "Protalix", "Ltd.", "s", "meeting", "a", "certain", "milestone.", "<tag2>", "Protalix", "Ltd.", "is", "also", "eligible", "to", "receive", "an", "additional", "up", "to", "$320", "million,", "in", "the", "aggregate,", "in", "regulatory", "and", "commercial", "milestone", "payments.", "<tag3>"], "wordsA": ["Pfizer", "paid", "Protalix", "Ltd.", "$60.0", "million", "as", "an", "upfront", "payment", "in", "connection", "with", "the", "execution", "of", "the", "Pfizer", "Agreement", "and", "subsequently", "paid", "to", "Protalix", "Ltd.", "an", "additional", "$5.0", "million", "upon", "Protalix", "Ltd.", "s", "meeting", "a", "certain", "milestone."], "wordsB": ["Protalix", "Ltd.", "is", "also", "eligible", "to", "receive", "an", "additional", "up", "to", "$320", "million,", "in", "the", "aggregate,", "in", "regulatory", "and", "commercial", "milestone", "payments."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p5_s0", "idA": "1006281_17_item7_p64_s1", "sentA": "Protalix Ltd. also received a milestone payment of $25.0 million in connection with the FDA s approval of taliglucerase alfa in May 2012.", "sentB": "Orphan Drug Designation for pegunigalsidase alfa qualifies Protalix Ltd. for access to a centralized marketing authorization procedure, including applications for inspections and for protocol assistance.", "type": 1, "words": ["<tag1>", "Protalix", "Ltd.", "also", "received", "a", "milestone", "payment", "of", "$25.0", "million", "in", "connection", "with", "the", "FDA", "s", "approval", "of", "taliglucerase", "alfa", "in", "May", "2012.", "<tag2>", "Orphan", "Drug", "Designation", "for", "pegunigalsidase", "alfa", "qualifies", "Protalix", "Ltd.", "for", "access", "to", "a", "centralized", "marketing", "authorization", "procedure,", "including", "applications", "for", "inspections", "and", "for", "protocol", "assistance.", "<tag3>"], "wordsA": ["Protalix", "Ltd.", "also", "received", "a", "milestone", "payment", "of", "$25.0", "million", "in", "connection", "with", "the", "FDA", "s", "approval", "of", "taliglucerase", "alfa", "in", "May", "2012."], "wordsB": ["Orphan", "Drug", "Designation", "for", "pegunigalsidase", "alfa", "qualifies", "Protalix", "Ltd.", "for", "access", "to", "a", "centralized", "marketing", "authorization", "procedure,", "including", "applications", "for", "inspections", "and", "for", "protocol", "assistance."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
{"idB": "1006281_18_item7_p6_s0", "idA": "1006281_17_item7_p64_s1", "sentA": "Protalix Ltd. also received a milestone payment of $25.0 million in connection with the FDA s approval of taliglucerase alfa in May 2012.", "sentB": "In January 2018, the FDA granted Fast Track designation to PRX-102.", "type": 1, "words": ["<tag1>", "Protalix", "Ltd.", "also", "received", "a", "milestone", "payment", "of", "$25.0", "million", "in", "connection", "with", "the", "FDA", "s", "approval", "of", "taliglucerase", "alfa", "in", "May", "2012.", "<tag2>", "In", "January", "2018,", "the", "FDA", "granted", "Fast", "Track", "designation", "to", "PRX-102.", "<tag3>"], "wordsA": ["Protalix", "Ltd.", "also", "received", "a", "milestone", "payment", "of", "$25.0", "million", "in", "connection", "with", "the", "FDA", "s", "approval", "of", "taliglucerase", "alfa", "in", "May", "2012."], "wordsB": ["In", "January", "2018,", "the", "FDA", "granted", "Fast", "Track", "designation", "to", "PRX-102."], "keywordsA": [], "keywordsB": [], "labels": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1], "probs": [-1, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, 0, -1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, -1]}
